Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
613 Leser
Artikel bewerten:
(2)

Aperam S.A.: Aperam announces the completion of its share buyback program

Finanznachrichten News

DJ Aperam announces the completion of its share buyback program

Aperam S.A. / Key word(s): Share Buyback Aperam announces the completion of its share buyback program 19-Apr-2022 / 16:45 CET/CEST

-----------------------------------------------------------------------------------------------------------------------

Luxembourg, 19 April 2022 (16:45 CET) - Aperam has completed its share buyback program announced on 11 February 2022 (hereafter the "Program"). In aggregate, 2,311,849 shares were bought under this Program, representing an equivalent amount of EUR 100 million.

-----------------------------------------------------------------------------------------------------------------------

Technical details regarding the share buyback program and treasury shares

Share buyback program - Corporate authorisation and key features of the Program

On 11 February 2022, Aperam announced a share buyback program under the authorization given by the annual general meeting of shareholders held on 7 May 2019 and, or under any renewal of such authorization at the May 4, 2022 annual general meeting of shareholders, with the following key features:

-- Purpose of the Program: cancellation of shares to reduce the share capital; and meeting obligationsarising from employee share programs

-- Maximum number of shares to be acquired under the Program: 2.5 million

-- Maximum pecuniary amount allocated to the Program: EUR 100 million

-- Period of authorisation of the Program: 14 February 2022 to 31 December 2022

The full details of the Program - including the Mittal family's intention to enter into a shares repurchase agreement with Aperam to maintain its voting rights in Aperam's issued share capital (net of Treasury Shares) at the same level, pursuant to the impact of the Program - are available in the press release dated 11 February 2022 (Link).

Share buyback program - Disclosure of trading in own shares under the completed Program

-- Period of repurchases: 18 February 2022 to 12 April 2022 (based on trade date)

-- Number of shares acquired: 2,311,849? Out of which on Euronext Amsterdam and other regulated dealing platforms: 1,364,915 - Out of which on Euronext off market platform from the Mittal family: 946,934

-- Pecuniary amount of shares acquired: EUR 100 million? Out of which on Euronext Amsterdam and other regulated dealing platforms: EUR 59.04 million - Out of which on Euronext off market platform from the Mittal family: EUR 40.96 million

The weekly detailed statements of own shares dealings made from 18 February 2022 to 12 April 2022 are available at the Company's website www.aperam.com, section Investors, Equity Investors, Share buy back (Link).

Treasury shares after completion of the Program (based on settlement date)

Number of treasury shares 
(a) Total number of treasury shares as of 31 December 2021:                         2,091,287 
 
(b) Additional number of treasury shares as a consequence of the share buyback program as of 19 April 2022: 
                                                      2,311,849 
(c) = (a) + (b) Total number of treasury shares as of 19 April 2022:                    4,403,136 

On 19 April 2022, the number of shares held by the Mittal family is 30,960,398. This amount corresponds to 40.96% of the issued shares (net of treasury shares).

About Aperam

Aperam is a global player in stainless, electrical and specialty steel, with customers in over 40 countries. As from 31.12.2021, the business is organised in four primary reportable segments: Stainless & Electrical Steel, Services & Solutions, Alloys & Specialties, and Recycling.

Aperam has a flat Stainless and Electrical steel capacity of 2.5 million tonnes in Brazil and Europe and is a leader in high value specialty products. In addition to its industrial network, spread over six production facilities in Brazil, Belgium and France, Aperam has a highly integrated distribution, processing and services network and a unique capability to produce stainless and special steels from low cost biomass (charcoal made from its own FSC-certified forestry). With ELG, Aperam is also a global leader in collecting, trading, processing and recycling of stainless steel scrap and high performance alloys, delivering 1.2 m tonnes of materials annually.

In 2021, Aperam had sales of EUR 5,102 million and steel shipments of 1.82 million tonnes.

For further information, please refer to our website at www.aperam.com.

Contact

Corporate Communications / Laurent Beauloye: +352 27 36 27 103

Investor Relations / Thorsten Zimmermann: +352 27 36 67 304

-----------------------------------------------------------------------------------------------------------------------

Dissemination of a Financial Wire News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

1330309 19-Apr-2022 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1330309&application_name=news

(END) Dow Jones Newswires

April 19, 2022 10:45 ET (14:45 GMT)

© 2022 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.